DelveInsight’s, “Urothelial Carcinoma Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Urothelial Carcinoma Pipeline Insight Report
Recent Developmental Activities in the Urothelial Carcinoma Pipeline Insight Report
Request a sample and discover more about the report offerings @ Urothelial Carcinoma Clinical Trials
Urothelial Carcinoma Overview
Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is by far the most common type of bladder cancer. Urothelial carcinomas are the fourth most common tumors after prostate, lung and colorectal cancer. This carcinoma is derived from the urothelium of the upper urinary tract (renal pelvis and ureter) or lower urinary tract (urinary bladder). In contrast with bladder urothelial carcinomas, upper urinary tract urothelial carcinomas (UTUCs) are relatively rare and account for only 5 to 10% of urothelial carcinomas. Development of targeted therapies for urothelial carcinoma is still in early stages, consequently there have been no major therapeutic advances to date. However, greater understanding of urothelial carcinoma and solid tumor biology has resulted in a proliferation of clinical trials that could lead to significant advances in treatment strategies. Although urothelial carcinoma is considered chemotherapy-sensitive, very few patients with metastatic disease are cured. Patients with a good prognosis can expect a median survival of 12–14 months. Approximately 70–80% of urothelial carcinoma is nonmuscle-invasive bladder cancer (NMIBC); the remaining 20–30% is muscle-invasive bladder cancer (MIBC) or metastatic. Almost 70% of patients with NMIBC will have disease recurrence within 2 years of diagnosis. Urothelial cells also line other parts of the urinary tract, such as the part of the kidney that connects to the ureter (called the renal pelvis), the ureters, and the urethra. People with bladder cancer sometimes have tumors in these places, too, so all of the urinary tract needs to be checked for tumors.
Urothelial Carcinoma Emerging Drugs
Pemazyre (pemigatinib): Incyte
Pemazyre (pemigatinib) is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test9. In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy. Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.
Cetrelimab: Janssen Research and Development
Cetrelimab is a Janssen discovered and developed investigational programmed cell death receptor-1 (PD-1) monoclonal antibody being studied in the treatment of bladder cancer, prostate cancer, and multiple myeloma as a combination treatment. Cetrelimab is also being evaluated in multiple combination regimens across the Janssen oncology portfolio.
Urothelial Carcinoma Pipeline Therapeutics Analysis
There are approx. 40+ key companies which are developing the therapies for Urothelial Carcinoma. The companies which have their Urothelial Carcinoma drug candidates in the most advanced stage, i.e. Phase III include Janssen Research and Development.
DelveInsight’s Urothelial Carcinoma Pipeline report covers around 50+ products under different phases of clinical development like
Learn more about the emerging Urothelial Carcinoma pipeline therapies @ Urothelial Carcinoma Pipeline Outlook
Scope of the Urothelial Carcinoma Pipeline Report
Table of content
Key Questions
Current Treatment Scenario and Emerging Therapies:
Got Queries? Get in touch with our Business Development Executive @ Urothelial Carcinoma Treatment
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/